SCHEMBL15068635

SCHEMBL15068635

CN1CCC(c2c(N)c(=O)oc3ccccc23)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
AGTR1 P30556 1/20 0.49
GAA P10253 12/20 0.49
KDM4E B2RXH2 8/20 0.49
MAPT P10636 6/20 0.46
LMNA P02545 1/20 0.46
PLA2G1B P04054 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 4/20 0.43
ALOX15 P16050 3/20 0.43
POLB P06746 2/20 0.43
ATM Q13315 1/20 0.42
TSHR P16473 1/20 0.41
HTR6 P50406 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15068899 0.92 GAA (0.51) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL15068632 0.91 GAA (0.48) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL15068615 0.85 GAA (0.47) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL16671456 0.84 GAA (0.46) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL15068897 0.83 GAA (0.50) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL15068612 0.76 GAA (0.46) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL16671454 0.75 GAA (0.44) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL10032003 0.71 ALDH1A1 (0.76) ALDH1A1AGTR1GAAKDM4EMAPT
SCHEMBL14081448 0.69 TNKS (0.47) ALDH1A1KDM4ELMNA
SCHEMBL1230426 0.68 GAA (1.00) ALDH1A1AGTR1GAAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 ALDH1A1 1006/4885AGTR1 4174/4885GAA 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.